Bright Minds Biosciences (CSE:DRUG) (OTCQB:BMBIF) CEO Ian McDonald explains to Proactive how the Vancouver, Canada-based group is aiming to be 'among, if not the leaders' of next-generation psychedelic drugs, while seeing 'a lot' of in-bound interest from Big Pharma for its psychedelic therapeutics.
McDonald says Bright Minds is moving to the clinic with its lead asset to treat epilepsy at the beginning of 2022, with a Phase 1 and Proof-of Concept Phase 2 trial.